Skip to main content
SpringerLink
Log in

A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two patients died from unrelated causes. One patient withdrew from the trial prior to receiving any chemotherapy. Sixteen patients either failed to respond or progressed during the course of the treatment. Side effects included nausea and vomiting in 6 patients and neutropenia in 6 patients. This study failed to detect a significant response of squamous cell carcinomas of the head and neck to mitoxantrone therapy at the described doses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Durr FE, Wallace RE, Citarella RV: Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 10:3–11, 1983

    Google Scholar 

  2. Niedhart JA, Gochnour D, Roach RW, Steinburg JA, Young D: Mitoxantrone vs Doxorubicin in advanced breast cancer: A randomised cross-over trial. Cancer Treat Rev 10:41–46, 1983

    Google Scholar 

  3. Prentice HG, Robbins G, Ma DDF, Ho AD: Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rev 10:57–63, 1983

    Google Scholar 

  4. Coltman Jr CA, McDaniel TM, Balcerzak SP, Morrison FS, Von Hoff DD: Mitoxantrone hydrochloride (NSC 310 739) in lymphoma. Invest New Drugs 1:63–71, 1983

    Google Scholar 

  5. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting the results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

  6. Rooney M, Kish J, Jabocs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hour 5-FU infusion and Cisplatin. Cancer 55:1123–1128, 1985

    Google Scholar 

  7. Mattox D, Clark C, Balcerzak S, O'Bryan R, Oishi N, Stuckey W: The Southwest Oncology Group Study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck. Invest New Drugs 2:405–407, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal North Shore Hospital, Sydney, Australia

    H. Wheeler & J. Levi

  2. Repatriation General Hospital, Concord, Sydney, Australia

    R. L. Woods & J. Page

Authors
  1. H. Wheeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. L. Woods
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Levi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wheeler, H., Woods, R.L., Page, J. et al. A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck. Invest New Drugs 8, 109–111 (1990). https://doi.org/10.1007/BF00216935

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216935

Key words

Search

Navigation